Synchron, Inc. was founded with the mission to revolutionize neurotechnology by addressing the limitations of the human body. The company focuses on developing brain-computer interfaces (BCIs) that enable individuals to control digital devices using their thoughts. Synchron's core product is a minimally-invasive BCI that can be implanted through an endovascular procedure, avoiding the need for open brain surgery. This technology aims to improve the quality of life for people with severe disabilities by providing them with new ways to interact with their environment.

Notable figures affiliated with Synchron include leading neuroscientists and medical professionals who contribute to the company's innovative approach. Synchron has garnered significant attention from investors interested in cutting-edge medical technology. Key achievements include successful clinical trials where participants have used the BCI to perform digital tasks, such as communicating with loved ones. The overall impact of Synchron's work is profound, offering new hope and independence to individuals with limited physical capabilities.